A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs BGS 649 (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors Mereo BioPharma
- 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2017 According to Mereo BioPharma media release, the company expects Top-line data from this study in Q1 2018.
- 08 Aug 2017 According to Mereo BioPharma media release, the company expects to enrolment (268 patients) in the coming weeks.